A Double-blind, Placebo-controlled Study to Evaluate the Effect of GS-6615 on QT, Safety and Tolerability in Subjects With Long QT2 Syndrome
Phase of Trial: Phase I
Latest Information Update: 15 Jul 2016
At a glance
- Drugs Eleclazine (Primary)
- Indications Long QT syndrome
- Focus Therapeutic Use
- Sponsors Gilead Sciences
- 11 Jul 2016 Status changed from active, no longer recruiting to completed.
- 23 May 2016 Status changed from recruiting to active, no longer recruiting.
- 15 Apr 2016 Planned End Date changed from 1 Apr 2016 to 1 Jun 2016.